Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated. -
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions. -
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing. -
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Early Monitoring of Chronic Myeloid Leukemia Might Dictate TKI Switch
Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Blast Count Prognostic for CML Presenting in Advanced Phase
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
